Medscape6d
The Correct Prednisone Starting Dose in Polymyalgia Rheumatica is Related to Body Weight But Not to Disease Severity
The only controlled study suggests that initial prednisone doses ≤ 10 mg is associated ... to test if 12.5 mg prednisone daily is an adequate starting dose in PMR and (b) to evaluate the factors ...
Medscape1d
The Correct Prednisone Starting Dose in Polymyalgia Rheumatica is Related to Body Weight But Not to Disease Severity
Our results support the hypothesis that a low initial dose of prednisone is sufficient to control PMR in the majority of patients. They also suggest that 0.20 mg per kg weight could be the ...
Dr. Roach: Ozempic dosage can be increased if/when a plateau is reached
Wegovy and Ozempic are the exact same drug: semaglutide. They are dosed slightly differently and marketed for different ...
Dear Doctor: Why have my cravings for sweets returned on my current dose of Ozempic?
They initially lost 40 pounds effortlessly, but now the weight is returning and so are the craving for sweets.
lupus.bmj1d
Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study
Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...
Cure Today16d
Epkinly Leads to Responses in Heavily Pretreated Patients With CLL
Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses ...
AFP12d
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) ...
Clinton Herald8d
TO YOUR GOOD HEALTH: Ozempic dosage can be increased if/when a plateau is reached
After about 10 months of being on Ozempic and working my way up to a 1-mg dose, I lost 40 pounds effortlessly. Sugar cravings ...
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
AbbVie (NYSE: ABBV) recently announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult ...